MPS Limited has announced a strategic investment of $16.5 million in Unbound Medicine and has now scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA. The company has formally notified stock exchanges about the conference call scheduled for February 18, 2026, marking a significant development in its North American healthcare technology expansion.

Conference Call Details

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, MPS Limited has scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA by MPS North America LLC, a wholly-owned subsidiary of the company.

Investment Structure and Strategic Approach

The $16.5 million investment combines both debt and equity components, providing MPS with a balanced financial structure for this strategic partnership. This mixed financing approach allows for optimal capital deployment while maintaining strategic flexibility in the partnership with Unbound Medicine.

Management Participation

Mr. Rahul Arora, Chairman and CEO, along with the senior management team of MPS Limited will be present to address the conference call. The company has provided multiple dial-in numbers including universal dial-in numbers, India national toll-free numbers, and international toll-free numbers for various countries including USA, UK, Singapore, Hong Kong, Australia, China, and Germany.

Strategic Implications

This acquisition represents MPS Limited's commitment to strengthening its foothold in the North American healthcare technology landscape through its subsidiary MPS North America LLC. The mixed debt-equity investment structure provides both companies with the financial flexibility needed to pursue aggressive growth strategies while maintaining operational independence. The partnership is expected to enhance both companies' competitive positioning in the rapidly evolving healthcare technology market.

MPS Infotecnics Limited has completed the mandatory newspaper publication of its unaudited financial results for the quarter and nine months ended December 31, 2025, in compliance with SEBI regulations, while continuing to face significant operational challenges with widening losses.

Regulatory Compliance and Publication

The company has fulfilled its regulatory obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing its financial results in Jansatta (Hindi Edition) and Financial Express (English Edition) on February 9, 2026. The results are also available on the company's website at www.mpsinfotec.com/newsroom.html .

Financial Performance Overview

The IT-enabled services company reported deteriorating financial performance across key metrics for Q3FY26. The company's total income from operations declined to ₹8.26 lakh in Q3FY26 from ₹11.11 lakh in the corresponding quarter of the previous year.

Earnings Per Share Analysis

The company's earnings per share metrics remained deeply negative, with both basic and diluted EPS at negative ₹0.002 for Q3FY26, consistent with the previous year's corresponding quarter. For the nine-month period, EPS deteriorated to negative ₹0.007 compared to negative ₹0.006 in the previous year.

Capital Structure and Board Governance

The company maintained its paid-up equity share capital at ₹37,744.37 lakh with a face value of ₹1 per share. The financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 7, 2026.

The company continues to face multiple regulatory compliance challenges, including outstanding listing fees to NSE and BSE, and pending SEBI penalties, while working to address these non-compliances as directed by stock exchanges.